Standout Papers

Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Pat... 2005 2026 2012 2019 728
  1. Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer (2005)
    William Kevin Kelly, Owen A. O’Connor et al. Journal of Clinical Oncology

Immediate Impact

9 by Nobel laureates 16 from Science/Nature 58 standout
Sub-graph 1 of 19

Citing Papers

Mechanisms and regulation of protein synthesis in mitochondria
2021 Standout
Network-based prediction of drug combinations
2019 Standout
2 intermediate papers

Works of Mark Heaney being referenced

Inhibition of Human Peptide Deformylase Disrupts Mitochondrial Function
2010
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics
2006
and 2 more

Author Peers

Author Last Decade Papers Cites
Mark Heaney 891 2110 1020 954 91 4.5k
Roshini S. Abraham 677 1664 1164 605 125 4.3k
Albert Deisseroth 644 2617 1075 2364 139 5.6k
Akio Urabe 552 1094 1496 1131 163 4.6k
Melvin H. Freedman 1175 1578 1752 1447 140 5.9k
Grover C. Bagby 649 2617 1619 864 129 5.4k
DW Golde 955 1596 1981 1095 125 6.2k
Didier Bouscary 1046 3414 2234 1391 161 6.2k
Yoichi Imai 418 2589 1504 1046 181 5.4k
Ulrich Jäger 1182 1799 2329 1618 173 5.5k
M Tulliez 1345 850 1070 1841 82 3.9k

All Works

Loading papers...

Rankless by CCL
2026